1,8-naphthyridin-2(1H)-one derivatives
AssigneeGrelan Pharmaceutical Co., Ltd.
InventorsTomoji Aotsuka, Kentarou Kumazawa, Nagatoshi Wagatsuma, Kouki Ishitani
Life of this patent
Estimating the term…
Loading patent…
AssigneeGrelan Pharmaceutical Co., Ltd.
InventorsTomoji Aotsuka, Kentarou Kumazawa, Nagatoshi Wagatsuma, Kouki Ishitani
Estimating the term…
The purpose is to provide selective PDE IV inhibitors which have a potent anti-asthmatic profile with excellent safety. A compound of the formula (1): wherein: A is an unsubstituted or optionally substituted 5 or 6 membered heteroaryl group or a fused benzene ring in which any of the above-defined heteroaryl groups is fused to a benzene ring, B is carbon or nitrogen, R1 is hydrogen, lower alkyl, trifluoromethyl, hydroxyl, lower alkoxy, a residue derived from a carboxylic acid or a derivative thereof, amino, or an amino nitrogen-containing group, R2 is hydrogen, halogen, cyano, nitro, lower alkylthio, lower alkylsulfinyl, lower alkylsulfonyl, trifluoromethyl, hydroxyl, lower alkoxy, a residue derived from a carboxylic acid or a derivative thereof, amino, or an amino nitrogen-containing group, and m is an integer of from 1 to 8, both inclusive; or a pharmaceutically acceptable salt thereof possesses selective PDE IV inhibition and is useful as a pharmaceutical drug, preferably an anti-asthmatic, etc.
A compound of the formula (1):
1-(3-Nitrophenyl)-3-(pyridin-3-ylmethyl)-1,8-naphthyridin-2(1H)-one.
1-(3-Nitrophenyl)-3-[3-(pyridin-4-yl)propyl]-1,8-naphthyridin-2(1H)-one.
1-(3-Methylthiophenyl)-3-[3-(pyridin-4-yl)-propyl]-1,8-naphthyridin-2(1H)-one.
Dependencies are inferred from the claim text.